MIBG Therapy for Neuroblastoma and Pheochromocytoma

MIBG therapy is a form of targeted radiation treatment that delivers radioactive iodine directly into certain tumor cells, primarily neuroblastoma in children and rare adrenal tumors called pheochromocytomas and paragangliomas in adults. The treatment exploits a biological quirk of these cancers: they actively pull in a molecule called MIBG (metaiodobenzylguanidine) through the same transport system that normally handles norepinephrine, a stress hormone. By attaching radioactive iodine-131 to MIBG, physicians can send a lethal dose of radiation straight to the cancer while largely sparing healthy tissue. The approach has been used for several decades and sits at an interesting intersection of nuclear medicine and oncology, with newer formulations and combination strategies continuing to reshape how it is delivered.

How the Treatment Gets Inside Tumor Cells

MIBG is a chemical cousin of norepinephrine, similar enough in structure that certain cancer cells mistake it for the real thing. Tumors that arise from neural crest tissue, the embryonic cells that give rise to the sympathetic nervous system, tend to produce a protein on their surface called the norepinephrine transporter (NET). This transporter normally recycles norepinephrine back into nerve cells, but it also grabs MIBG and pulls it inside.¹ Once inside the cell, the iodine-131 attached to the MIBG molecule decays, releasing beta particles that damage DNA and kill the cell.² Because most healthy tissues do not express NET at high levels, the radiation concentrates in the tumor rather than blanketing the whole body.

The same molecule, labeled with a different form of radioactive iodine (iodine-123 instead of iodine-131), serves as a diagnostic imaging agent. An iodine-123 MIBG scan lights up wherever NET-expressing tumor cells are hiding, and roughly 90% of neuroblastomas show uptake on this scan.³ That dual role makes MIBG a classic “theranostic” agent: one molecule used first to find the disease and then to treat it.

Neuroblastoma and MIBG

Neuroblastoma is the most common solid tumor outside the brain in children, and high-risk cases remain difficult to cure. MIBG therapy has become one of the principal tools for children whose disease has relapsed or failed to respond to standard chemotherapy. The treatment is not a guaranteed cure, but response rates across studies typically range from about a quarter to nearly half of patients, depending on how response is defined and what other treatments are combined with MIBG.

A large retrospective study of patients treated with iodine-131 MIBG found an overall response rate of 27%, with important differences between patients whose disease had come back after an initial response (relapsed) and those whose disease never fully responded to earlier treatment (refractory). Refractory patients fared better after MIBG: their two-year overall survival was about 65%, compared with roughly 39% for relapsed patients.⁴ That gap is a reminder that the biology of each child’s disease shapes the outcome at least as much as the treatment itself.

More recent approaches have intensified the strategy. A prospective study using tandem high-activity MIBG infusions combined with the chemotherapy drug melphalan and autologous stem cell rescue reported an overall response rate of 48% and a three-year overall survival of 55%.⁵ Another analysis of high-dose MIBG in relapsed high-risk neuroblastoma found a five-year overall survival rate of about 41%, with factors like the extent of skeletal disease and whether the child had relapsed more than once influencing the prognosis.⁶

Pheochromocytoma and Paraganglioma in Adults

MIBG therapy is not only a pediatric treatment. Adults with metastatic pheochromocytomas (tumors of the adrenal gland) and paragangliomas (tumors of nerve tissue outside the adrenal gland) can also benefit. These tumors are rare but can cause dangerous surges in blood pressure and other hormone-driven symptoms. Because they share the same neural crest origin as neuroblastoma, many of them take up MIBG avidly.

A phase II trial of high-dose MIBG in 49 evaluable patients with metastatic pheochromocytoma or paraganglioma reported a combined complete and partial response rate of 22%, with an additional 35% of patients achieving a response in at least one measured parameter without their disease progressing.⁷ A smaller study reported even higher figures: an objective tumor response in 47% of patients, a biochemical response in 67%, and symptom improvement in 89%.⁸ Numbers vary across studies because patient populations, doses, and definitions of response differ, but the consistent finding is that most patients get meaningful symptom relief even when the tumor itself does not shrink dramatically on imaging.

A long-term follow-up of 125 patients treated with MIBG for metastatic pheochromocytoma or paraganglioma found that three-quarters of those assessed reported symptomatic improvement, with pain relief being the most common benefit, followed by reduced fatigue and better blood pressure control.⁹ For patients living with hormone-secreting tumors that cause daily misery, that kind of palliative benefit matters enormously even when complete tumor eradication is not achieved.

Side Effects and Blood Count Recovery

The most predictable side effect of MIBG therapy is a drop in blood cell counts. The bone marrow is sensitive to circulating radiation, and after a high-dose MIBG infusion, white blood cells and platelets fall. For that reason, many treatment protocols include an autologous stem cell rescue: the patient’s own stem cells are collected beforehand and reinfused after therapy to speed marrow recovery. In one early pilot combining MIBG with myeloablative chemotherapy, the median time to neutrophil recovery was 10 days and platelet recovery took about 28 days.¹⁰ A later phase I study of double-infusion MIBG reported slightly different timelines, with neutrophil recovery at a median of 13 days and platelet independence at 17 days.¹¹ During that vulnerable window, patients are at risk for infections and bleeding and require close monitoring.

Mouth sores (oral mucositis) are another common complaint, particularly when MIBG is combined with chemotherapy. In adults with pheochromocytoma or paraganglioma, acute blood pressure spikes during the MIBG infusion are a recognized concern, because the unlabeled MIBG molecules in conventional preparations can displace norepinephrine from nerve terminals and trigger a catecholamine surge.¹² Less common but serious toxicities recorded in the phase II pheochromocytoma trial included lung problems, infections during periods of low white blood cell counts, and hormonal changes like low sex hormone levels.¹³

Thyroid Protection

Free radioactive iodine released during the breakdown of MIBG in the body can be taken up by the thyroid gland, potentially causing hypothyroidism or thyroid damage. To prevent this, patients receive potassium iodide (and sometimes potassium perchlorate) before and during therapy. The idea is to flood the thyroid with stable, non-radioactive iodine so it has no room to absorb the radioactive version.¹⁴ Studies suggest this prophylactic regimen works well, resulting in low rates of significant hypothyroidism after treatment.¹⁵ Still, thyroid function is monitored long-term after MIBG therapy, because some patients develop subclinical or overt hypothyroidism months or years later.

Medications That Can Interfere

Because MIBG relies on the norepinephrine transporter to get into tumor cells, any drug that blocks or competes for that transporter can reduce treatment effectiveness. A comprehensive review of medication interactions found medium-to-strong evidence that tricyclic antidepressants, certain calcium channel blockers, and the heart medication amiodarone can all lower MIBG uptake. The evidence was considered strong enough to recommend stopping labetalol (a blood pressure drug) and tricyclic antidepressants before MIBG imaging or therapy.¹⁶ Other medications that affect norepinephrine handling, including some common antidepressants beyond the tricyclic class, are also flagged for washout before treatment. Patients scheduled for MIBG therapy typically receive a detailed list of drugs to avoid, sometimes weeks in advance.

The High Specific Activity Formulation

Conventional MIBG preparations have a fundamental limitation: more than 99% of the MIBG molecules in the vial are unlabeled, carrying no radioactive iodine at all. These “cold” molecules still compete for the same transporter on tumor cells, effectively crowding out the radioactive ones. Worse, in patients with catecholamine-secreting tumors, those cold molecules can displace norepinephrine and cause dangerous blood pressure crises. Up to 14% of patients with pheochromocytoma or paraganglioma receiving conventional MIBG experienced severe acute hypertension during infusion.¹⁷

A high-specific-activity (HSA) formulation was developed to address both problems. In HSA MIBG, nearly every molecule in the preparation carries a radioactive iodine atom, dramatically reducing the amount of unlabeled drug administered. The specific activity jumps from about 3.3 mCi per milligram in conventional preparations to roughly 2,500 mCi per milligram. In clinical trials, no patients receiving the HSA formulation experienced severe hypertension or hypertensive crises during infusion.¹⁸ This formulation was approved by the FDA in 2018 for adults with certain inoperable, locally advanced, or metastatic pheochromocytomas and paragangliomas.

Radiation Isolation and What to Expect

Because the patient becomes a temporary source of radiation after receiving iodine-131, MIBG therapy requires inpatient isolation. The specifics vary by institution, but the general framework involves a private room (sometimes lead-lined, though studies have shown rolling lead shields can substitute), a urinary catheter to collect radioactive urine safely, and restricted visitor access until the radiation level drops below a set threshold.¹⁹ Typically, one or two designated caregivers receive radiation safety training and are permitted to stay nearby, sometimes in an adjacent room, to provide comfort and basic care.²⁰ Isolation usually lasts a few days, though the exact duration depends on how quickly the patient’s radiation level falls.

For children with neuroblastoma, this isolation period is often the most psychologically challenging part of the treatment. A qualitative study of children and their parents found that emotional stress was common among the young patients, though most felt adequately prepared. Screen-based entertainment and video calling helped pass the time. Parents generally reported that the experience was not as bad as they had feared, and that it became easier if they had to go through it more than once.²¹ Nonetheless, families consistently identify practical burdens: limited access to psychosocial support services during isolation, financial strain from travel and lost work time, and the enforced separation from siblings and extended family.²²

Combination Strategies

MIBG is increasingly used alongside other treatments rather than as a standalone therapy. The rationale is straightforward: radiation damages DNA, and some chemotherapy drugs or other agents may make tumor cells more vulnerable to that damage, or may mop up cells that MIBG alone does not kill. A randomized phase II trial compared three approaches for children with relapsed or refractory neuroblastoma: MIBG alone, MIBG with vincristine and irinotecan, and MIBG with the epigenetic drug vorinostat. The MIBG-plus-vorinostat arm showed the highest response rate at 32%, compared with 14% for each of the other two arms.²³ This finding has spurred further investigation into radiosensitizing combinations.

Combining MIBG with myeloablative chemotherapy followed by stem cell rescue is another well-studied approach, essentially using MIBG as an upfront debulking tool before the chemotherapy finishes the job. The tandem high-activity MIBG study mentioned earlier is one example of this philosophy, and some protocols now integrate MIBG into the initial treatment plan for newly diagnosed high-risk neuroblastoma rather than reserving it for relapse.

Tailoring the Dose

One of the ongoing challenges in MIBG therapy is figuring out how much radiation each individual patient needs. Traditional approaches use a fixed dose based on body weight, but tumors vary enormously in how avidly they take up MIBG and how quickly they clear it. Patient-specific dosimetry, where imaging data from a tracer study or a prior treatment is used to calculate radiation absorption in the tumor and in critical organs, allows physicians to individualize the dose. Centers that use this personalized approach report that it enables delivery of higher activities that the patient can still tolerate, particularly when stem cell support is available.²⁴

Professional guidelines have been developed to standardize how dosimetry calculations are performed, covering the acquisition of imaging data, timing of measurements, and the mathematical models used to estimate absorbed dose to the whole body, to the tumor, and to organs at risk like the liver and kidneys.²⁵ In practice, many centers still rely on weight-based dosing because dosimetry infrastructure requires specialized equipment and expertise. But the field is moving toward greater individualization, driven by the recognition that the same administered dose can deliver very different radiation exposures to the tumor in different patients.

Long-Term Risks and Second Cancers

Because MIBG therapy involves whole-body exposure to ionizing radiation, there is an inherent risk of late effects, including second malignancies. A study tracking 644 neuroblastoma patients who received MIBG found that 19 developed a second cancer afterward. The cumulative incidence was about 7.6% at five years and 14.3% at ten years. Most of these second cancers were blood-related malignancies like acute myeloid leukemia and myelodysplastic syndrome, which are known complications of radiation and alkylating chemotherapy. A smaller number were solid tumors, including thyroid cancer and osteosarcoma.²⁶

Interpreting these numbers requires context. Children with high-risk neuroblastoma receive many other treatments that also carry a second-cancer risk, including alkylating agents, topoisomerase inhibitors, and external beam radiation. Disentangling MIBG’s specific contribution from the cumulative effect of an entire treatment history is difficult. What the data do tell us is that long-term surveillance after MIBG therapy is essential, particularly monitoring blood counts for signs of myelodysplasia and checking thyroid function regularly.

How MIBG Compares With Newer Targeted Radionuclides

MIBG is not the only radioactive drug aimed at neuroendocrine tumors. Lutetium-177 DOTATATE (sold as Lutathera) targets a different receptor, the somatostatin receptor, and has become a standard treatment for certain gastroenteropancreatic neuroendocrine tumors. The two therapies overlap in some patient populations, particularly paragangliomas, and the choice between them (or the sequencing of them) often depends on which receptor the individual tumor expresses more strongly. A review of neuroendocrine tumor patients treated with either lutetium-177 DOTATATE or iodine-131 MIBG at a single center found both could produce responses, even in challenging sites like orbital metastases.²⁷ Head-to-head trials between the two agents are limited, and in practice, the choice is guided by imaging: if the tumor lights up more on an MIBG scan, MIBG therapy is favored; if it shows stronger somatostatin receptor expression on a DOTATATE PET scan, lutetium therapy gets the nod.

For neuroblastoma specifically, MIBG remains the dominant targeted radionuclide therapy because neuroblastoma cells reliably express the norepinephrine transporter. Somatostatin receptor expression in neuroblastoma is more variable, making DOTATATE-based approaches less consistently applicable in that disease. Research is ongoing, but for now, MIBG is still the workhorse radionuclide therapy for neuroblastoma and for MIBG-avid pheochromocytomas and paragangliomas.

Outpatient Possibilities

The need for inpatient radiation isolation is one of the biggest logistical hurdles of MIBG therapy. It limits the number of centers that can offer the treatment and adds to the burden on families. Some investigators have explored whether lower-activity MIBG treatments could be given safely in an outpatient setting. Measured radiation exposure rates to caregivers and the public after outpatient radionuclide therapy have been found to fall within international regulatory guidelines in some settings, suggesting that outpatient delivery could be cost-effective and safe when permitted by local regulations.²⁸ However, the high doses used in neuroblastoma therapy typically exceed the thresholds that would allow immediate discharge, so outpatient delivery remains more feasible for lower-dose palliative applications than for the aggressive protocols used in pediatric oncology. Institutional rules and national radiation safety regulations vary widely, adding another layer of complexity.